National Comprehensive Cancer Network

About NCCN

NCCN Flash Update: NCCN Guidelines® & NCCN Compendium® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs and Biologics Compendium (NCCN Compendium®) for Acute Lymphoblastic Leukemia. These NCCN Guidelines® are currently available as Version 2.2017.

  • Relapsed/Refractory Disease (ALL-9)
    • Ph-positive ALL
      • Inotuzumab ozogamicin (category 2A) added as a treatment option for patients with disease refractory/intolerant to TKIs.
    • Ph-negative ALL
      • Inotuzumab ozogamicin (category 1) added as a treatment option.
  • Regimens for Relapsed/Refractory ALL (ALL-D 3 of 5)
    • Footnote "j" added: Inotuzumab ozogamicin is associated with hepatotoxicity, including fatal and life-threatening hepatic veno-occlusive disease, and increased risk of post-hematopoietic stem cell transplant (HSCT) non-relapse mortality. For details, see: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf.  
    • Ph-positive ALL
      • Inotuzumab ozogamicin (category 2A) added as a treatment option for patients refractory/intolerant to TKIs.
    • Ph-negative ALL
      • Inotuzumab ozogamicin (category 1) added as a treatment option.

 

*For your reference, the previous update (Version 1.2017) to the NCCN Guidelines for Acute Lymphoblastic Leukemia, published on June 1, 2017, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf

 

 

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium®, the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.

Free NCCN Guidelines apps for iPhone, iPad, and Android smartphones & tablets are now available! Visit NCCN.org/apps

About NCCN Flash Updates™ 
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)
275 Commerce Drive, Suite 300
Fort Washington, PA 19034
Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2017 National Comprehensive Cancer Network. All Rights Reserved.